217 related articles for article (PubMed ID: 35570208)
1. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
Zeng Q; Xiang B; Liu Z
Ann Hematol; 2022 Aug; 101(8):1711-1718. PubMed ID: 35570208
[TBL] [Abstract][Full Text] [Related]
2. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
3. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.
Saraceni F; Labopin M; Gorin NC; Blaise D; Tabrizi R; Volin L; Cornelissen J; Cahn JY; Chevallier P; Craddock C; Wu D; Huynh A; Arcese W; Mohty M; Nagler A;
J Hematol Oncol; 2016 Sep; 9(1):79. PubMed ID: 27589849
[TBL] [Abstract][Full Text] [Related]
4. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
[TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
6. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Efficacy of Modified BU/CY as Conditioning Regimen Combined with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Young Acute Myeloid Leukemia Patients with Low or Intermediate Risk].
Zhang JH; Zhang AL; Dong CX; Qin XQ; Zhang RJ; Ge XY; Kang JM; Hou YF; Zhang YF; Guo JL; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):360-364. PubMed ID: 30998138
[TBL] [Abstract][Full Text] [Related]
9. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
[TBL] [Abstract][Full Text] [Related]
10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective analysis of prognosis in favorable-risk acute myeloid leukemia patients with different consolidation regimens].
Wang HY; Bao XB; Tang XW; Sun AN; Wu DP; Zhou HX; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):517-522. PubMed ID: 28655096
[No Abstract] [Full Text] [Related]
12. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
[TBL] [Abstract][Full Text] [Related]
13. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia.
Tao S; Zhou D; Song L; Deng Y; Chen Y; Ding B; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2231733. PubMed ID: 37408450
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission.
Jing Y; Li H; Zhao Y; Bo J; Wang S; Wang Q; Huang W; Gao C; Yu L
Bone Marrow Transplant; 2013 Mar; 48(3):383-9. PubMed ID: 23000651
[TBL] [Abstract][Full Text] [Related]
16. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
17. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis.
Ye W; Wu X; Zhao R; Jin X; Li H; Qu Y; Ji J; Liu Z
Stem Cell Res Ther; 2024 May; 15(1):153. PubMed ID: 38816870
[TBL] [Abstract][Full Text] [Related]
18. Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation
Yegin ZA; Dikyar A; Aydın Kaynar L; Can F; Özkurt ZN; Yağcı M
Hematol Rep; 2020 Dec; 12(3):8380. PubMed ID: 33324478
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Activated Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia].
Ren RR; Ma LM; Wang T; Xie YX; Zhu QJ; Gao ZL; Tian WW; Gong R; Niu YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1509-1515. PubMed ID: 37846709
[TBL] [Abstract][Full Text] [Related]
20. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
